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Carotid artery stenting outcomes are equivalent to
carotid endarterectomy outcomes for patients with
post-carotid endarterectomy stenosis
Ali F. AbuRahma, MD,a Shadi Abu-Halimah, MD,a Stephen M. Hass, MD,a
Aravinda Nanjundappa, MD,a Patrick A. Stone, MD,a Albeir Mousa, MD,a Erik Lough, MD,a
and L. S. Dean, PhD, MBA,b Charleston, WV
Background: Carotid artery stenting (CAS) has been advocated as an alternative to redo surgery for patients with
post-carotid endarterectomy (CEA) stenosis. This study compares early and late clinical outcomes for both groups.
Methods:This study analyzes 192 patients: 72 had reoperation (Group A) and 120 had CAS for post-CEA stenosis (Group
B). Patients were followed prospectively and had duplex ultrasounds at 1 month, and every 6 to 12 months thereafter.
The perioperative complications (perioperative stroke, myocardial infarction/death, cranial nerve injury) and 4-year end
points were analyzed. A Kaplan-Meier lifetable analysis was used to estimate rates of freedom from stroke, stroke-free
survival, >50% restenosis, and >80% restenosis.
Results: Demographic/clinical characteristics were comparable for both groups, except for diabetes mellitus and coronary
artery disease, which were significantly higher in Group B. The indications for reoperations were transient ischemic
attacks/stroke in 72% for Group A versus 57% for Group B (P  .0328). The mean follow-up was 33 months (range, 1-86
months) for Group A and 24months (range, 1-78months) for Group B (P .0026). The proportion of early (<24months)
carotid restenosis prior to interventionwas 51% inGroupA versus 27% inGroupB (P .0013). The perioperative stroke rates
were 3% and 1%, respectively (P  .5573). There were no myocardial infarctions or deaths in either group. The overall
incidence of cranial nerve injury was 14% for Group A versus 0% for Group B (P< .0001). However, there was no statistical
difference between the groups relating to permanent cranial nerve injury (1% versus 0%). The combined early and late stroke
rates for Groups A and B were 3% and 2%, respectively (P .6347). The stroke-free rates at 1, 2, 3, and 4 years for Groups A
andBwere 97%, 97%, 97%, and 97% and 98%, 98%, 98%, and 98%, respectively (P .6490). The stroke-free survival rates were
not significantly different. The rates of freedom from>50% restenosis at 1, 2, 3, and 4 years were 98%, 95%, 95%, and 95% for
Group A versus 95%, 89%, 80%, and 72% for Group B (P .0175). The freedom from>80% restenosis at 1, 2, 3, and 4 years
forGroupsA andBwere 98%, 97%, 97%, and97%versus 99%, 96%, 92%, and87%, respectively (P .2281). Four patients (one
symptomatic) in Group B had reintervention for>80% restenosis. The rate of freedom from reintervention for Groups A and
B were 100%, 100%, 100%, and 100% versus 94%, 89%, 83%, and 79%, respectively (P  .0634).
Conclusions:CAS is as safe as redo CEA. Redo CEA has a higher incidence of transient cranial nerve injury; however, CAS
has a higher incidence of >50% in-stent restenosis. ( J Vasc Surg 2010;52:1180-7.)Carotid artery stenting (CAS) has emerged as an alter-
native to carotid endarterectomy (CEA) for patients with
anatomical and physiological high-risk features; one such
anatomical high-risk feature is post-CEA stenosis.1-3
Patients who undergo CEA are at risk of developing
post-CEA stenosis ranging from 1% to 36%,4-6 and the stan-
dard of care for the treatment of this post-CEA stenosis has
not been established. Redo CEA is often challenging due to
scar tissue in the field, identification of anatomic structures
(particularly cranial nerves),7-9 neurological events, wound
complications, hematoma, and death. The last decade has
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1180seen a rise in the number of CAS procedures performed, and
one of the approved indications for CAS is post-CEA stenosis.
Our present study is the largest study to compare the short-
and long-term clinical outcomes of CAS versus redo CEA for
post-CEA stenosis from the same institution.
PATIENT POPULATION AND METHODS
This study includes 192 patients with post-CEA
stenosis who underwent intervention (CAS or reopera-
tion) between 1996 and 2008 at our institution. Patients
who had CAS for post-CEA stenosis were considered by
their surgeons to be too high-risk for conventional reop-
eration due to previous neck irradiation, high cervical
lesions (based on previous CEA findings), or past cranial
nerve injuries. Others had CAS simply because their
surgeons (general and cardiac surgeons with vascular
privileges) felt they were too morbid for reoperations.
Also, more recently, patients were more likely to choose
CAS over reoperation after a thorough discussion of the
pros and cons of each procedure. Therefore, most of the
reoperations were done prior to June 2000; after that,
only 14 patients had reoperations. It should be noted
that the number of CEAs done in our tertiary medical
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the past 12-year period of this study. We also average
around 15 to 20 CAS procedures annually. Our indica-
tions for carotid reintervention included patients with
80% asymptomatic (including progressive carotid ste-
nosis) or 50% symptomatic post-CEA stenosis. This
study was approved by our Institutional Review Board,
and written informed consent was obtained from all
patients.
The demographic/clinical characteristics and intra-
operative data were collected by chart review and from
the Circulatory Dynamic Laboratory (CDL) records.
The CDL is an independent invasive vascular laboratory
with an advanced imaging system (Advantx; General
Electric System, Milwaukee, Wisc), located outside the
cardiac catheterization labs and operating rooms. All
patients underwent a baseline preoperative carotid color
duplex ultrasound (done at a vascular laboratory accred-
ited by the Intersocietal Commission for Accreditation
of Vascular Laboratories), with or without computed
tomography angiography (CTA) or magnetic resonance
angiography (MRA), followed by carotid arteriograms
prior to intervention. We utilized our previously pub-
lished criteria for optimal carotid duplex velocity for
defining the severity of post-CEA stenosis.10 Specifically,
an internal carotid artery (ICA) peak systolic velocity
(PSV) of 155 cm/sec was optimal in detecting 30%
restenosis, a PSV 213 cm/sec was optimal in detecting
50% restenosis, and an ICA PSV of 275 cm/sec was
optimal for detecting 70% restenosis.
All redo CEAs were performed under general anesthe-
sia with systemic heparin and routine shunting using a
carotid Argyle shunt (C. R. Bard, Inc, Billerica, Mass).
Forty patients underwent redo with carotid patching
(Gore-tex [W. L. Gore & Associates, Flagstaff, Ariz], Fi-
nesse [Boston Scientific Corp, Natick, Mass], bovine, and
ACUSEAL [W. L. Gore & Associates] polytetrafluoroeth-
ylene patches), and 32 underwent re-endarterectomy with
patch angioplasty. None of these patients had interposi-
tional grafts.
All reinterventions (redo CEA or CAS) were done
within 30 days from the onset of symptoms in symptomatic
patients, except for one patient where the reoperation was
done 5 weeks after the onset of symptoms.
Carotid angioplasty and stenting protocol. Our
technique for CAS has been described and published pre-
viously.1,11 It should be noted that all procedures were
done using distal cerebral protection devices, according to
various carotid protocols used in our institution. CAS was
excluded in the following patients: severely angulated/
tortuous carotids, thrombus containing lesions, and diffi-
cult aortic arch (Type III/IV arch). Pre-dilatation was done
in most patients (severe/tight stenosis) prior to filter inser-
tion using 3 or 4 mm balloons. Post-dilatation using 5 mm
balloons was also performed after stent deployment to
achieve optimal stent strut position.
All patients were prescribed a regimen of 325 mg of
aspirin and 75 mg of clopidogrel (Plavix) daily for 3 to 5days prior to the CAS, which was followed by a regimen of
75 mg of clopidogrel (Plavix) and 325 mg aspirin daily
postoperatively. Plavix was continued for 6 weeks, and
aspirin was continued indefinitely.
Post-procedural cerebral CT/MRI scans were only
performed on patients with documented neurological
events (transient ischemic attacks [TIA] or strokes). They
also had independent preoperative and postoperative neu-
rological evaluations by neurologists.
Post-reoperation and CAS surveillance and long-
term follow-up. All patients had immediate postoperative
carotid duplex ultrasounds, which were repeated at 30 days
and every 6 to 12 months.
The long-term follow-up data were assessed by pa-
tient examination in the Vascular Center of Excellence at
our institution. For practical purposes, and to comply
with the standard classification of carotid stenosis, we
used a cutoff of 30% stenosis to indicate normal to
minimal disease. Carotid stenoses were, therefore, clas-
sified into 30% to 49%, 50% to 79%, and 80% to 99%
stenoses. Angiographic measurement of the stenoses was
calculated according to the North American Symptom-
atic Carotid Endarterectomy Trial, basically by compar-
ing the narrowest segment of the carotid stent to the
diameter of the distal normal ICA where the walls be-
come parallel.12 We utilized our previously published
criteria for optimal carotid duplex velocity for defining
severity of carotid in-stent stenosis.11 Specifically, an
ICA PSV of 154 cm/sec was optimal for the diagnosis
of 30% carotid in-stent stenosis, an ICA PSV of 224
cm/sec was optimal for the diagnosis of 50% carotid
in-stent stenosis, and an ICA PSV of 325 cm/sec was
optimal for the diagnosis of 80% carotid in-stent ste-
nosis. We also utilized our previously published criteria
for defining severity of post-CEA stenosis.10 All patients
with 80% in-stent stenosis or 80% stenosis after re-
operation, as defined by duplex ultrasound, underwent
further imaging, including CTA and/or carotid arteriog-
raphy for confirmation of the diagnosis or further inter-
vention.
The clinical end points included TIAs (resolving
within 24 hours), a minor stroke (defined as a neurolog-
ical deficit persisting longer than 24 hours, resulting in
Grade I or II Rankin scale), or a major stroke (Grades
III-V Rankin scale). A stroke was referred to as an
ipsilateral stroke if it affected the same cerebral hemi-
sphere of the carotid intervention or a contralateral
stroke if it affected the contralateral cerebral hemisphere.
Myocardial infarction (MI) was defined as a Q-wave
MI as noted in two or more leads, or non Q-wave MI as
noted by elevation of creatine kinase (CK) levels to
greater than three times the upper limit of normal in the
presence of elevated CK-MB (greater than upper limit of
normal) and in absence of new Q-wave in two or more
leads.
Statistical methods. The statistical comparison of
continuous data were examined with the unpaired Stu-
dent’s t test, and the discrete variables were compared with
JOURNAL OF VASCULAR SURGERY
November 20101182 AbuRahma et althe 2 or Fisher’s exact test. The time to occurrence of
events (time to 50% restenosis, 80% restenosis, or
stroke or death) was calculated using the Kaplan-Meier
method. Statistical comparisons were made with the log-
rank test.
RESULTS
This study included 192 patients: 72 had reoperations
(Group A) and 120 had CAS (Group B) for post-CEA
stenosis. The mean follow-up was 33 months (range, 1-86
months) for Group A and 24months (range, 1-78months)
for Group B (P  .0026).
As noted in Table I, the demographic and clinical
characteristics were comparable for both groups, except for
diabetes mellitus and coronary artery disease, which were
significantly higher in Group B. Group B also had a signif-
icantly lower number of patients with symptomatic carotid
disease as indications for CAS. The proportion of early
post-CEA stenosis (24 months) was 51% in Group A
Table I. Demographics and clinical characteristics
Group A
N  72
Group B
N  120
P
value
Gender: female 40 (56%) 54 (45%) .1566
Hypertension 78% 85% .2044
Diabetes mellitus 27% 43% .0247
Coronary artery disease 51% 77% .0003
Hypercholesterolemia 61% 60% .8789
Smoking 63% 59% .6475
Chronic obstructive pulmonary
disease
8% 8% .835
Chronic renal insufficiency 17% 21% .4785
Mean follow-up 33 months 24 months .0026
Indications for procedure
Symptomatic (transient
ischemic attack/stroke)
72% 57% .0328
Asymptomatic 28% 43%
Original carotid endarterectomy
to reoperation 24
months
51% 27% .0013
Table II. 30-day perioperative complications
Group A
(N  72)
Group B
(N  120)
Total
(N  192)
P
value
Perioperative
ipsilateral
strokes
2 (3%) 1 (1%) 3 (2%) .5573
Ipsilateral transient
ischemic
attack
1 (1%) 3 (3%) 4 (2%) 1
Myocardial
infarction
0 0 0
Death 0 0 0
Bleeding 1 (1%)
Total cranial nerve
injury
10 (14%) 0 10 (5%) .0001
Transient 9 (13%) 0 9 (5%) .0001
Permanent 1 (1%) 0 1 (1%) .375versus 27% in Group B (P  .0013).Early (30-day) perioperative outcome. Table II
summarizes the perioperative stroke, death, and other com-
plications. As noted in Table II, the perioperative stroke
rates were 3% for Group A versus 1% for Group B (P 
.5573). The perioperative strokes in Group A included one
major and one minor stroke. Both patients had reoperation
for symptomatic indications; one for post-CEA stenosis of
over 24months and one for stenosis of less than 24months.
The one stroke in Group B was done for symptomatic
post-CEA stenosis of over 24 months. All strokes were felt
to be embolic in nature. There were no perioperative MIs
or deaths in either group. The cranial nerve injury rate was
14% in Group A versus 0% in Group B (P  .0001).
However, nine of these patients had transient cranial nerve
injuries (12.5%), and only one patient (1.4%) had a perma-
nent cranial nerve injury (P  .375).
Late clinical outcome. The combined early and late
strokes for Groups A and B were 3% and 2%, respectively
(P  .6347). There was one late stroke in Group B, which
was not associated with50% in-stent stenosis. The stroke-
free rates at 1, 2, 3, and 4 years for Groups A and B were
97%, 97%, 97%, and 97% and 98%, 98%, 98%, and 98%,
respectively (P  .6558; Fig 1). The stroke-free survival
rates at 1, 2, 3, and 4 years were 96%, 92%, 87%, and 79%
for Group A and 94%, 89%, 83%, and 79% for Group B (P
.7144; Fig 2). None of the late deaths (6 in Group A and 13
in Group B) were secondary to stroke.
There were six patients (9%) in Group A versus 17
patients (15%) in Group B with 50% restenosis (P 
.2175). The rate of freedom from 50% restenosis at 1, 2,
3, and 4 years were 98%, 95%, 95%, and 95% for Group A
versus 95%, 89%, 80%, and 72% for Group B (P  .0175;
Fig 3). Only one patient with 50% restenosis (80%) in
Group B had a TIA, and the remaining patients were
asymptomatic. There were four patients (6%) with 80%
restenosis for Group A versus seven patients (6%) for Group
B (P  1). The freedom from 80% restenosis at 1, 2, 3,
and 4 years for Groups A and B were 98%, 97%, 97%, and
97% versus 99%, 96%, 92%, and 87%, respectively (P 
.2281; Fig 4).
Four patients in Group B with 80% in-stent stenosis
had reintervention (three had re-stenting and one had
PTA); three were asymptomatic and one had TIAs. The
rate of freedom from reintervention for Groups A and B
were 100%, 100%, 100%, and 100% versus 94%, 89%, 83%,
and 79%, respectively (P  .0634; Fig 5).
DISCUSSION
The incidence of post-CEA stenosis has been reported
to range from 1% to 36%.4-6 However, only 1% to 8% of
all CEA patients will develop hemodynamically significant
restenosis.
Restenosis occurring within 6 to 24 months after
intervention is usually attributed to neointimal fibrous
hyperplasia, whereas late recurrence of disease after 24
months is chiefly due to progression of atherosclero-
sis.4,5,13 The importance of this distinction is that neo-
dom
from
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not likely to embolize, making percutaneous translumi-
nal angioplasty and/or stenting an attractive treatment
option in this situation.
For years, redo CEA has been the standard treatment for
post-CEA stenosis. While it is generally agreed upon by most
experts that reoperation for significant symptomatic post-
CEA stenosis is indicated, there is some controversy regarding
Fig 1. Free
Fig 2. Freedomthe indications for reoperation for asymptomatic restenosis.7-9This is largely due to the inherent risks in any open reinter-
vention in a previously operated field, such as increased scar
tissue, which can obscure tissue planes andmake identification
of anatomic structures and surgical landmarks more challeng-
ing. Reoperation can have morbidity and mortality rates as
high as 8% to 20%,13-20 although recent literature suggests
that this is improving.6,21-23
O’Donnell et al reported on the results from a meta-
from stroke.
stroke/death.analysis of six series that showed a 4.2% stroke rate and a 1%
from
from
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the incidence of cranial nerve injury in these patients aver-
aged 8.5%.9 Hill et al reported a much lower 30-day stroke
and death rate of 0% for reoperation versus 1.1% for primary
CEA.23 This study compared only 40 reoperations against
350 primary operations, and the results may simply rein-
force the difference in the pathophysiology between ath-
Fig 3. Freedom
Fig 4. Freedomerosclerotic disease found mostly in primary lesions andneointimal fibrous hyperplasia often seen in recurrent dis-
ease. A 5-year stroke-free survival rate of 92% and a freedom
from severe restenosis rate of 89% at 5 years with redo CEA
have been published.4,24,25
CAS has been advocated by some investigators as an
alternative to reoperation for post-CEA carotid steno-
sis.1,15,19,26-31 Lanzino et al found no major periproce-
50% restenosis.
80% restenosis.dural neurologic deficits or deaths with 25 CAS on 21
rget-
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338 patients, demonstrated a 3.7% 30-day stroke and death
rate with a minor stroke rate of 1.7%.29
In spite of the positive results for CAS in these studies,
only a few reports with a small number of patients have
directly compared CAS to redo CEA for post-CEA steno-
sis.4,15,30-32 Hobson et al compared 16 cases treated by
reoperation with 15 cases treated with CAS over an 8-year
period.15 No 30-day strokes or deaths were reported, and
no restenosis or stent occlusion was found in the CAS
group over a 7-month follow-up period.15
Bowser et al compared 27 reoperations over a 9-year
period with 52 CAS procedures over a 5-year period.30
Overall 30-day morbidity was similar between the two
groups (12% vs 11%), and the combined stroke and death
rate was 3.7% for reoperation and 5.7% for CAS (P .1).30
Stenosis-free ICA patency at 36 months was 75% for reop-
eration and 57% for CAS.30 Recently, Bettendorf et al
evaluated outcomes of CAS versus redo CEA in treating
recurrent stenosis.31 Interestingly, they found secondary
recurrence to be higher after redo CEA (14% vs 6.1%);
however, this was not statistically significant.31
Most recently, Attigah et al retrospectively evaluated
early and midterm results of redo CEA and CAS in 79
consecutive patients (86 arteries), including 41 CEA and
45 CAS procedures.32 There were four neurological com-
plications in the CEA group and one in the CAS group
(P .13). Wound site and cardiac complication rates were
significantly higher in the CEA group (P  .029), with a
median follow-up of 35 months. After 60 months, the
overall actuarial survival rate was 83% in the CEA group and
100% in the CAS group (P  .87). Freedom from repeat
intervention for re-recurrence was 89% in the CEA group
Fig 5. Freedom from taand 95% in the CAS group (P .52). They concluded thatsurvival and freedom from reintervention were not signifi-
cantly different between the two groups.
Our current study is the largest comparative evaluation of
reoperation versus CAS for post-CEA stenosis analyzing 72
carotid reoperations with 120CAS.Not only does it reinforce
the feasibility of CAS in this situation, but it demonstrated
equivalency between CAS and reoperation for post-CEA ste-
nosis. There was no statistically significant difference observed
between CAS andCEAwith regard to the primary end points
of perioperative stroke, myocardial infarction, and/or death.
However, there was an increased incidence of transient cranial
nerve injuries for redo CEA, in contrast to an increased inci-
dence of50% in-stent restenosis in patients who underwent
CAS. Meanwhile, the freedom from 80% restenosis at 4
years was equivalent in both groups.
Another issue regarding CAS for recurrent stenosis, in
comparison to redo surgery, is durability. When recurrent
stenosis after CEA is treated with CAS, in-stent restenosis
can be as high as 13% at 14 months, as reported by
Rockman et al,33 and up to 24% at 20 months, as described
by AbuRahma et al.4 To be noted, these high in-stent
restenosis rates in our earlier experience can be explained by
the fact that we used the carotid duplex velocity criteria for
native carotids (ie, these rates are probably falsely high).
However, Hobson et al reported no restenosis or stent
occlusion at 7 months.15 de Borst et al recently described
their experience with 57 CAS on 55 patients with post-
CEA stenosis and evaluated the durability of CAS in this
situation over a longer follow-up period.26 The cumulative
rates of in-stent restenosis-free survival at 1, 2, 3, and 4
years were 93%, 85%, 82%, and 76% with cumulative rates
of freedom from reintervention at 1, 2, 3, and 4 years of
96%, 94%, 90%, and 84%.26 They concluded that CAS for
vessel revascularization.recurrent carotid artery stenosis not only appears techni-
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stenosis rates appear high, requiring both early and longer
term follow-up surveillance.
While our findings in this study cannot refute the higher
incidence of recurrent stenosis of CAS as compared with redo
CEA, our study demonstrated a rate of freedom from 50%
in-stent restenosis at 4 years of 72% and a freedom from80%
in-stent restenosis at 4 years of 87% for CAS patients.
Our study has limitations because it was a retrospective
chart review; however, all of the CAS patients were part of
several prospective carotid stent trials. A direct comparison of
CEA versus CAS is difficult in this retrospective study because
many patients who underwent CAS in the earlier years were
considered nonsurgical candidates because of the high cervical
location of the lesion, previous cranial nerve injury, or severe
comorbidities. It should be noted that a greater proportion of
patients undergoing redoCEAwere symptomatic (72% vs 57%);
however, patients who underwent CAS hadmore comorbidities
(coronary artery disease and diabetes mellitus). We also at-
temptedtocreateasmuchuniformityaspossible inour twostudy
groups in order to draw an accurate comparison.
In conclusion, CAS is as safe as redo CEA. RedoCEA has
a higher incidence of transient cranial nerve injury; however,
CAS has a higher incidence of50% in-stent restenosis.
We would like to acknowledge Mary Emmett, PhD,
CharlestonAreaMedicalCenter, for her assistance on this paper.
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